Reuters logo
BRIEF-Capricor Therapeutics provides update on Natriuretic Peptide program
February 16, 2017 / 10:32 PM / 10 months ago

BRIEF-Capricor Therapeutics provides update on Natriuretic Peptide program

Feb 16 (Reuters) - Capricor Therapeutics Inc

* Provides update on Natriuretic Peptide program

* Elected to terminate license agreement with Mayo Clinic relating to Natriuretic Peptide receptor agonists, including Cenderitide

* Says expect to file an investigation new drug application for CAP-2003 in second half of this year Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below